Therapy Expectations
In US clinical trials, Soliris® reduced chronic hemolysis in every treated patient, including those with bone marrow disorders such as aplastic anemia (AA) or myelodysplastic syndromes (MDS). Other benefits occurred in the following time frames:
Important things to consider
Soliris is an ongoing therapy. Since PNH is a chronic disease, patients who start Soliris should continue receiving Soliris, even if they feel better.2 If for some reason you and your doctor determine to stop Soliris therapy, only your doctor can safely manage taking you off the drug.
You may have other conditions besides PNH. People with PNH may have other medical conditions that affect the function of their bone marrow such as aplastic anemia (AA) or myelodysplastic syndromes (MDS). These diseases may reduce the production of blood cells and further complicate PNH.5 If you have PNH in combination with AA or MDS, talk to your doctor — it’s important to effectively treat all the conditions you may have.
Considerations while on Soliris
It is important to understand that some medications you are taking, specifically blood thinners, should not be changed without consulting your doctor. Please make sure your doctor knows about all the medications you are taking.